Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC CTU at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years.  

The podcast mini-series will explore the trial from different perspectives by talking to neurologists, MS experts and people affected by MS.  

Part 1 covers the treatment and research landscape of MS and the challenges of treating progressive MS. It features Jeremy Chataway, neurologist at the National Hospital for Neurology and Neurosurgery at UCLH, Professor of Neurology at UCL and co-lead of the Neurodegenerative Diseases progamme at the MRC CTU at UCL, who is leading the Octopus trial. We also hear from Dawn Lyle, Lead Research MS Nurse, and Matthew Justin, MS Specialist, who are based at the Anne Rowling Regenerative Neurologic Clinic in Edinburgh.  
-
For more information and to access the transcript: https://bit.ly/3S6FKP4

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

Octopus (part 1): The MS landscape with Jeremy Chataway, Dawn Lyle and Matthew Justin

The Trial Talk podcast explores how our work at the MRC Clinical Trials Unit at UCL is improving health in the UK and worldwide. In this series, we hear from world-leading experts about the studies we carry out. We delve into trials on cancer, infections and neurodegenerative diseases, explore how public and patient involvement shapes our work, and discover new ways to run smarter studies.

Octopus (part 1): The MS landscape with Jeremy Chataway, Dawn Lyle and Matthew Justin

MRC CTU at UCL - Trial Talk podcast